605033.SH
Shaanxi Meibang Pharmaceutical Group Co., Ltd.
SSE · Basic Materials · Agricultural Inputs · CN
CNY 17.29
+1.95%Oct 21, 2026, 08:02 UTC
Meibang reported third-quarter 2026 revenue of CNY 145 million, net profit of CNY 870,200 and adjusted net loss of CNY 881,200; for the first nine months, revenue was CNY 700 million, net profit was CNY 51.9376 million and adjusted net profit was CNY 45.2586 million.
Source:Sep 4, 2026, 07:48 UTC
Meibang Co. announced it will use 1 million US dollars of its own funds to establish a wholly-owned subsidiary Meibang Pharmaceutical (Hong Kong) Co., Ltd. in Hong Kong, with a registered capital of 500,000 Hong Kong dollars.
Source:Sep 4, 2026, 07:48 UTC
Meibang Co. announced it will inject 80 million yuan of its own funds into its wholly-owned subsidiary Shaanxi Nuozheng Biotechnology Co., Ltd., increasing the subsidiary's registered capital from 100 million yuan to 180 million yuan, with Meibang's 100% stake unchanged.
Source: